CHAPTER 386 Adjuvant Endovascular Management of Brain Arteriovenous Malformations
Clinical Significance and Treatment Plan
Treatment of AVMs often requires a multidisciplinary approach with a team consisting of an interventional neuroradiologist, a vascular neurosurgeon, a vascular neurologist, and a stereotactic radiosurgeon.1–5 Such a team provides a balanced approach to management of the AVM.
Patient Selection
The discovery of an AVM in a patient does not represent an immediate indication for treatment. Each AVM does not carry the same risk for future hemorrhage.6 An incidentally discovered cortical micro-AVM in a young patient does not have the same prognosis and natural history as a large thalamic AVM in a young patient with a progressive neurological deficit or hemorrhage.
Clinical Analysis
Age
In general, the younger the patient at the time of diagnosis, the more likely treatment should be considered. Diagnosis at a young age represents an early imbalance between the patient (i.e., host) and the AVM, and the patient has a greater number of years at risk for hemorrhage. Increasing age and age older than 60 years have also been found to be risk factors for hemorrhage.6,7 Older patients likewise have a greater risk for hemorrhage-associated morbidity and mortality than younger individuals do; therefore, treatment may even be warranted in the elderly.
Gender
The gender of the patient should not influence the decision to treat a brain AVM. Although there has been controversy about the risk for hemorrhage or other symptoms in women, especially during pregnancy, this association has not been well established. The majority of studies demonstrate that pregnancy or delivery does not seem to increase the risk for hemorrhage or the risk for progression of neurological symptoms.8–11
Initial Symptoms
Hemorrhage
Although some controversy exists regarding the rebleeding rate during the first year after hemorrhage, it is generally believed to be similar to or just slightly higher than the natural history risk of 2% to 4% per year.12–20 Each episode of hemorrhage is associated with a 10% risk for mortality and a 30% to 50% morbidity rate.35 A study by Ondra and coworkers analyzed the outcome of symptomatic AVMs. They reported a severe morbidity rate of 1.7%, annual mortality rate of 1%, and a mean rebleeding interval of greater than 6 years.18
When the benefits of treatment outweigh the risks associated with treatment in patients with a history of AVM hemorrhage, the angioarchitecture of the AVM is meticulously analyzed in search of areas of anatomic weakness. The pattern of hemorrhage may correspond with a particular feature, such as a feeding artery or perinidal aneurysm. If such an abnormality is discovered, targeted embolization can be performed (Figs. 386-1 to 386-3).8,21 If the source of hemorrhage can be occluded by embolization, surgical resection may be deferred to allow more complete recovery. If embolization of high-risk or causative malformations is technically impossible or unsuccessful, early surgical resection may be necessary. Although treatment philosophies vary depending on local expertise, the universal goal should be to reduce or eliminate the risk for future hemorrhage with acceptable treatment-associated risk.
Seizures
Many patients initially seen with a seizure disorder can be treated successfully with antiepileptic medications and rarely require immediate intervention. Patients with seizures carry the same future risk for hemorrhage as those with other symptomatic AVMs. Seizures do not alter the risk for future hemorrhage.18 When indicated, both microsurgery and radiosurgery have demonstrated similar results in reducing the incidence of seizures attributable to AVMs and the need for anticonvulsant therapy.22–24 Embolization has little role in the specific treatment algorithm of patients with seizures, except as an adjuvant to definitive treatment planning.
Headaches
Headache is a nonspecific symptom. Some patients with AVMs that have a dural or posterior cerebral artery supply complain of headaches that resolve or improve after embolization.25 Other patients with parietal lobe AVMs complain of worsening headache after embolization of anterior and middle cerebral artery feeders if there is a compensatory increased supply through the posterior cerebral arteries. Headaches by themselves do not represent an indication for treatment of patients with AVMs because the risk for hemorrhage is not changed from that of the general population.
Neurological Deficit
Up to 40% of patients with AVMs have neurological deficits,26 but neurological deficits are uncommon in patients without history of hemorrhage. In our experience and in the reports of others, neurological deficits are present in more than half of patients.25 Although arterial steal and mass effect have been implicated as possible causes,27 venous congestion and ischemia are also probable mechanisms (Fig. 386-4).25 Magnetic resonance imaging (MRI) has demonstrated changes in the venous drainage patterns of adjacent brain tissue with associated edema and partial thrombosis of draining veins of the AVM. If treated by partial embolization, these changes may be reversible in lobar AVMs causing progressive neurological deficits. Partial embolization of deep thalamic and basal ganglia AVMs in patients with progressive neurological deficits has been reported to result in stabilization in 27% and reversal of symptoms in 64% (see Fig. 386-3).28 Further definitive therapy should be carried out to completely obliterate the AVM and remove the risk for future hemorrhage, when possible.
Architecture of the Arteriovenous Malformation
A decision to treat depends, in part, on the demonstration of areas of weakness in the angioarchitecture indicating potential instability. If there is an associated arterial aneurysm on the feeding pedicle or in the nidus, evidence of venous thrombosis, restriction of outflow, venous hypertension, venous pouches or dilations, venous pseudoaneurysm, or compromised venous outflow, treatment may be indicated and can achieve cure in certain circumstances, or targeted treatment as an adjuvant to definitive treatment may be beneficial (Fig. 386-5; see also Figs. 386-1 to 386-4).
A number of radiologic variables have been associated with an increased risk for hemorrhage, including small AVM size, elevated feeding artery pressure, periventricular or intraventricular location, basal ganglia location, deep venous drainage, impaired venous drainage, single draining vein, intranidal aneurysm, multiple aneurysms, and vertebrobasilar blood supply.15,29–36
Data from the New York Islands AVM Hemorrhage Study, an ongoing, prospective, population-based survey to determine the incidence of AVM-related hemorrhage and the associated rates of morbidity and mortality in a zip code–defined population of 10 million people, showed that increasing age (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.03 to 1.08), initial hemorrhagic AVM manifestation (HR, 5.38; 95% CI, 2.64 to 10.96), deep brain location (HR, 3.25. 95% CI, 1.30 to 8.16), and exclusive deep venous drainage (HR, 3.25; 95% CI, 1.01 to 5.67) were independent predictors of subsequent hemorrhage. Annual hemorrhage rates on follow-up ranged from 0.9% in patients without a hemorrhagic AVM manifestation, deep AVM location, or deep venous drainage to as high as 34.4% in those harboring all three risk factors.6,12,20 The authors also studied predictors of residual dysplastic vessels on cerebral angiography after AVM treatment. The number of patients showing angiographic evidence of dysplastic vessels was significantly associated with increasing size of the AVM, and symptomatic postoperative intracerebral hemorrhage was associated with dysplastic vessels on the postoperative angiogram.37
Location, Size, and Deep Venous Drainage
Although the location, size, and deep venous drainage of a malformation are important factors in determining the risks associated with microsurgical or radiosurgical therapy,38 these factors are of lesser concern in the endovascular treatment of AVMs. In performing embolization of AVMs, meticulous technique is important to prevent embolization of nontarget tissue and stroke (see Fig. 386-5).
Associated Lesions
Aneurysms are associated with AVMs in 10% to 40% of patients.39–42 Such aneurysms may be flow related (i.e., proximal or distal on a feeder vessel), intranidal, or remote and apparently unrelated (Figs. 386-6 and 386-7; see also Fig. 386-2).39–42 This weakness represents a marker for future hemorrhage and increases the risk for hemorrhage from 3% to 7%.13 Patients with subarachnoid hemorrhage, intracerebral hemorrhage, or both and an angiographically demonstrated AVM with an associated aneurysm should have therapy directed first toward the lesion that is suspected to be the source of hemorrhage. In the presence of acute subarachnoid hemorrhage, the source of hemorrhage is often a feeding artery aneurysm. When an intracerebral hematoma exists, the more likely source of hemorrhage is the AVM, including nidal and perinidal locations (see Fig. 386-3). Enlarging pseudoaneurysms represent an unstable situation and deserve special attention to prevent early hemorrhage. Ventricular hemorrhage or parenchymal hemorrhage may be venous in origin.
High blood flow to an AVM may induce aneurysms to form on feeding arteries. Such “flow-related” aneurysms may regress after complete or partial obliteration of the AVM by endovascular embolization, and regression is more likely to occur the closer the aneurysm is to the nidus of the AVM.41 If the aneurysm is located close to the AVM, it should be obliterated at the time of embolization. If the aneurysm is within the planned resection field, it may be clipped at the time of microsurgery. If on follow-up angiography 6 to 12 months after AVM embolization there is no regression of the associated aneurysm, active treatment of the aneurysm should be considered. We recommend treating large, irregular, proximal aneurysms early as part of a global treatment plan (see Figs. 386-4 and 386-5). However, the treatment-associated morbidity must be low to justify the procedure in light of the unknown natural history of the aneurysm in the absence of the AVM.
Treatment Goals
Endovascular embolization is most commonly used as an adjunct to surgical resection or stereotactic radiosurgery. Embolization can be performed as the sole treatment (curative or palliative) in carefully selected patients, or it may result in excessive complications.43
Curative Embolization
Curative embolization is discussed in greater detail elsewhere in this textbook. The prerequisite for curing an AVM with endovascular embolization techniques alone is angioarchitecture that permits solid casting of the AVM nidus with permanent embolization material. Curative embolization is complete anatomic obliteration of the malformation by endovascular embolization, occlusion of the nidus, and early venous shunting, and it therefore requires the use of a permanent, nonbiodegradable embolic agent to form a cast within the pathologic angioarchitecture (Fig. 386-8). Particles or resorbable agents should not be used for curative embolization.
In addition to the immediate postembolization angiogram, 6-month and, preferably, 12- to 24-month postprocedural angiograms are useful to confirm the durability of treatment. Long-term angiographic follow-up is needed to detect small remnants that may not have been appreciated on the immediate postembolization angiogram and to exclude recanalization caused by the radiopaque embolic material mixing with nonopaque autologous blood at the time of embolization.44–46